Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance
Author:
Publisher
China Science Publishing & Media Ltd.
Subject
General Medicine,Biochemistry,Biophysics
Link
https://engine.scichina.com/doi/pdf/7311F1DD993C41F2B65F234A831E81A6
Reference92 articles.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin, 2022, 72: 7-33.
2. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ (Clinical research ed) 2020, 371: m3773.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011, 144: 646-674.
4. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med, 2011, 365: 2473-2483.
5. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol, 2015, 16: 928-936.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. TCF3 as a multidimensional biomarker: oncogenicity, genomic alterations, and immune landscape in pan-cancer analysis;Acta Biochimica et Biophysica Sinica;2024-08-01
2. Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis;Biomedicine & Pharmacotherapy;2024-07
3. Direct antitumor activity of bevacizumab: an overlooked mechanism?;Frontiers in Pharmacology;2024-04-23
4. Metabolism related gene signature predicts prognosis and indicates tumor immune infiltration in ovarian cancer;European Journal of Gynaecological Oncology;2024
5. Exploring the underlying biology of cancer and potential therapeutic strategies: a special issue focused on mechanism-based studies;Acta Biochimica et Biophysica Sinica;2023-06-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3